{"id":"W4210750855","doi":"10.1016/j.annonc.2022.01.076","title":"Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Atezolizumab; Medicine; Vemurafenib; Internal medicine; Hazard ratio; Oncology; Confidence interval; Cancer; Pembrolizumab; Immunotherapy; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009269548,0.0003127187,0.0008594397,0.0002164842,0.0001500404,0.000438046,0.0002097197,0.0003286751,0.001598693],"category_scores_gemma":[0.001524667,0.0002457977,0.001286985,0.0001618625,0.0002176008,0.000359529,0.000271738,0.000617343,0.0001220602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000410959,"about_ca_system_score_gemma":0.0003181481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002951518,"about_ca_topic_score_gemma":0.0006106825,"domain_scores_codex":[0.9996279,0.0001758841,0.00003107026,0.00007810341,0.00003444147,0.00005247392],"domain_scores_gemma":[0.9993425,0.0002520801,0.0002178272,0.00003934639,0.00001856904,0.0001297272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4325898,0.002029713,0.4512407,0.0002888247,0.00208553,0.0001659454,0.0001383331,0.006487132,0.01487549,0.0002204109,0.0007418825,0.0891362],"study_design_scores_gemma":[0.02962326,0.08905786,0.8453183,0.00008389301,0.002880215,0.0005999393,0.0001965472,0.02175846,0.007146864,0.001306799,0.001944562,0.0000832963],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.999263,0.0002975877,0.000140292,0.00003344166,0.000006710611,0.0000262354,0.000131791,0.000004399919,0.00009656191],"genre_scores_gemma":[0.9995339,0.00005240742,0.0001445891,0.00001992075,0.000006040389,0.00002762441,0.0001480532,6.138569e-7,0.00006681178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001598693,"threshold_uncertainty_score":0.005348146,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03356083637505654,"score_gpt":0.3065765158893343,"score_spread":0.2730156795142777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}